MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA – Get Free Report) saw a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 447,300 shares, a growth of 2,610.9% from the July 15th total of 16,500 shares. Based on an average daily trading volume, of 4,750,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.7% of the shares of the company are short sold.
Wall Street Analyst Weigh In
Separately, Ascendiant Capital Markets began coverage on shares of MIRA Pharmaceuticals in a research note on Monday, August 5th. They set a “buy” rating and a $11.00 price target on the stock.
Read Our Latest Stock Report on MIRA
MIRA Pharmaceuticals Stock Up 0.5 %
MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Research analysts predict that MIRA Pharmaceuticals will post -0.62 EPS for the current fiscal year.
Institutional Trading of MIRA Pharmaceuticals
Institutional investors have recently bought and sold shares of the company. Praetorian Wealth Management Inc. purchased a new stake in shares of MIRA Pharmaceuticals in the first quarter valued at about $30,000. Cross Staff Investments Inc purchased a new position in shares of MIRA Pharmaceuticals during the 1st quarter worth approximately $422,000. Suncoast Equity Management acquired a new position in shares of MIRA Pharmaceuticals during the 1st quarter worth approximately $44,000. Finally, Virtu Financial LLC lifted its stake in MIRA Pharmaceuticals by 330.2% in the 1st quarter. Virtu Financial LLC now owns 63,055 shares of the company’s stock valued at $69,000 after buying an additional 48,397 shares in the last quarter. 35.16% of the stock is currently owned by hedge funds and other institutional investors.
About MIRA Pharmaceuticals
MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
See Also
- Five stocks we like better than MIRA Pharmaceuticals
- The How And Why of Investing in Oil Stocks
- How to Invest in Silver: A Beginner’s Guide
- What is a Secondary Public Offering? What Investors Need to Know
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Roth IRA Calculator: Calculate Your Potential Returns
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.